morpholinoanthracycline mx2 has been researched along with decitabine in 1 studies
| Studies (morpholinoanthracycline mx2) | Trials (morpholinoanthracycline mx2) | Recent Studies (post-2010) (morpholinoanthracycline mx2) | Studies (decitabine) | Trials (decitabine) | Recent Studies (post-2010) (decitabine) |
|---|---|---|---|---|---|
| 53 | 15 | 0 | 3,804 | 205 | 2,177 |
| Protein | Taxonomy | morpholinoanthracycline mx2 (IC50) | decitabine (IC50) |
|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, M; Asano, T; Fujii, H; Fukunaga, Y; Hasegawa, K; Horichi, N; Isoe, T; Nakamura, K; Ohmori, T; Otake, N | 1 |
1 other study(ies) available for morpholinoanthracycline mx2 and decitabine
| Article | Year |
|---|---|
Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Blotting, Northern; Carubicin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Immunoblotting; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |